Cardiovascular Prevention and Pharmacotherapy

Original Article

Age-stratified association between isolated diastolic hypertension and carotid intima-media thickness: results from the Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) Study: Minsung Cho, Jiyen Han, Hansol Choi, Jee-Seon Shim, Sun Jae Jung, Hokyou Lee, Hyeon Chang Kim; Cardiovasc Prev Pharmacother. 2025;7(4):109-119. Published online October 24, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e18

738 View
16 Download

Abstract PDF Supplementary Material: Background
The clinical significance of isolated diastolic hypertension (IDH), particularly in relation to subclinical vascular changes, remains unclear and may vary across age groups. This study evaluated the age-stratified association between IDH and carotid intima-media thickness (IMT).
Methods
This cross-sectional study included 6,759 Korean adults aged 30–64 years from the Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. Participants with a history of cardiovascular disease or use of antihypertensive medication were excluded. Blood pressure was classified according to the 2017 American College of Cardiology/American Heart Association guidelines into four categories: no hypertension, IDH, isolated systolic hypertension, and systolic diastolic hypertension. Carotid IMT was measured by B-mode ultrasonography, and vascular thickening was defined as IMT ≥0.857 mm (75th percentile). Multivariable logistic regression analyses were performed with age stratification.
Results
Among participants younger than 50 years, IDH was significantly associated with carotid IMT thickening after adjustment for age, sex, body mass index, educational attainment, physical activity, smoking, diabetes, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering drug use, C-reactive protein, and study site (odds ratio [OR], 1.57; 95% confidence interval [CI], 1.10–2.26). No significant association was observed in participants aged 50 years or older (OR, 0.89; 95% CI, 0.72–1.09). Both isolated systolic hypertension and systolic diastolic hypertension were associated with carotid IMT thickening in all age groups.
Conclusions
IDH was associated with subclinical vascular changes in younger adults but not in older adults. These findings highlight the age-specific nature of the association of IDH with cardiovascular risk.

Review Articles

Next-generation PCSK9 inhibitors: clinical evidence and future directions for cardiovascular prevention: Hyun-Jin Kim; Cardiovasc Prev Pharmacother. 2025;7(4):141-145. Published online October 22, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e17

6,788 View
28 Download

Abstract PDF: Low-density lipoprotein cholesterol (LDL-C) is a causal and modifiable risk factor for atherosclerotic cardiovascular disease, and intensive reduction of LDL-C is central to prevention strategies. Meta-analyses have shown that each 1 mmol/L (approximately 38.7 mg/dL) decrease in LDL-C confers about a 22% relative risk reduction in major vascular events, independent of baseline LDL-C levels. Despite the proven efficacy of statins and ezetimibe, many patients fail to reach recommended LDL-C targets due to inadequate response, intolerance, or poor adherence to daily therapy. The development of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has transformed lipid management, providing substantial LDL-C reduction. Recently, next-generation agents with extended dosing intervals have emerged, including recaticimab, a fully human monoclonal antibody, and inclisiran, a small interfering RNA therapy. Recaticimab binds circulating PCSK9, preventing degradation of the low-density lipoprotein receptor, and achieves sustained LDL-C reductions of about 50% with dosing every 8 to 12 weeks. Inclisiran employs N-acetylgalactosamine (GalNAc)-mediated hepatocyte delivery to silence PCSK9 messenger RNA, producing comparable LDL-C reductions with twice-yearly maintenance dosing after an initial loading dose. Their extended dosing schedules offer potential benefits in adherence and long-term lipid control, particularly for high-risk patients who struggle with frequent dosing or have statin intolerance. As outcome data accumulate, these therapies may further reduce residual atherosclerotic cardiovascular disease risk and become increasingly important in comprehensive prevention strategies.

Physical activity for prevention of cardiovascular disease: a consensus statement of the Korean Society of Cardio-cerebrovascular Disease Prevention: Ye Seul Yang, Eu Jeong Ku, Seung-Hyun Ko, Eun-Jung Rhee, Sang-Hyun Ihm, Sung Hee Choi, Won-Young Lee; Cardiovasc Prev Pharmacother. 2025;7(4):120-134. Published online September 15, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e15

926 View
19 Download

Abstract PDF: Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, highlighting the need for effective preventive strategies. This consensus statement emphasizes the critical role of regular physical activity, including aerobic and muscle- strengthening exercises, in reducing key CVD risk factors such as hypertension, dyslipidemia, obesity, and insulin resistance. Recommendations are provided for the general adult population as well as specific subgroups, including older adults, pregnant and postpartum women, individuals with CVD, and those with physical limitations. The importance of reducing sedentary behavior and integrating physical activity into daily life is also addressed. Recommendations should focus on tailored interventions, supportive environments, and evidence-based policies that encourage active lifestyles. Further research specific to the Korean population will enhance the development of evidence-based, population-tailored guidelines for more effective CVD prevention in Korea.

Original Articles

2024 Cardio-cerebrovascular disease fact sheet in Korea: Kyungdo Han, Jin-Hyung Jung, Sang-Suk Choi, Seung-Hyun Ko; Cardiovasc Prev Pharmacother. 2025;7(3):85-93. Published online July 29, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e13

7,017 View
88 Download
1 Citations

Abstract PDF

Background
Cardiovascular disease (CVD) is the second most common cause of death in Korea. We investigated the incidence rate of CVD in the Korean adult population using the Korean National Health Insurance Service database.
Methods
This cohort included individuals aged 20 years and older who participated in the National Health Screening Program in 2012, and longitudinal follow-up data were collected through December 2022. The incidence of CVD, myocardial infarction, ischemic stroke, and cardiovascular mortality was evaluated. The incidence of CVD in relation to key cardiovascular risk factors was also analyzed.
Results
A total of 4,737,616 participants were included in the final analysis. The mean age was 47.9 years, with a slight male predominance (54.1%). Older age, male sex, and current smoking were consistently associated with higher risk across all CVD outcomes. The overall adjusted incidence rate was 288.9 per 100,000 person-years for CVD. The 1.6-fold higher incidence of CVD in individuals with type 2 diabetes mellitus, 1.5-fold higher incidence in those with hypertension, and 1.4-fold in those with metabolic syndrome clearly demonstrate the cumulative risk conferred by these comorbidities. The most pronounced increase in cardiovascular mortality was observed in individuals with chronic kidney disease, reaching a 2.0-fold higher rate.
Conclusions
CVD and its comorbidities in the Korean adult population represent a significant health burden. Prompt and aggressive lifestyle modification and management of risk factors should be actively emphasized.

Citations

Citations to this article as recorded by

Comparison of ischemic cardiovascular events between dapagliflozin and empagliflozin in combination with metformin: A nationwide population-based cohort study
Hayeon Kim, Seung Won Lee, Yejee Lim, Nayoung Han, Suin Kang, Youngjoo Byun, Kyungim Kim, Marwan Salih Al-Nimer
PLOS One.2025; 20(10): e0333604. CrossRef

The distribution of artificial intelligence–derived retinal cardiovascular risk scores and conventional risk factors in two Korean health screening cohorts: a descriptive study: Jungkyung Cho, Jaewon Seo, Junseok Park, Dongjin Nam, Tae Hyun Park, Sahil Thakur, Tyler Hyungtaek Rim, Beom-hee Choi, Miso Jang; Cardiovasc Prev Pharmacother. 2025;7(3):73-84. Published online July 28, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e14

2,915 View
52 Download

Abstract PDF Supplementary Material: Background
Although retinal imaging–based artificial intelligence (AI) tools have recently been introduced for cardiovascular disease (CVD) risk assessment, little is known about the distribution of these AI-derived scores across the full age spectrum or their associations with traditional cardiometabolic risk factors at different ages.
Methods
We analyzed data from 138,745 participants who underwent routine health examinations at two health screening centers in Seoul, Korea. The AI-based retinal CVD risk score (Dr.Noon CVD), as well as anthropometric, hemodynamic, and metabolic indices and cardiometabolic disease status, were compared across ages 16 to 96 years. In a subgroup of 13,182 individuals who underwent coronary artery calcium scoring (CACS) by cardiac computed tomography, we evaluated the performance of the Dr.Noon CVD score in detecting CACS using receiver operating characteristic curve analysis.
Results
Mean Dr.Noon CVD scores rose steadily with age from 14.2±2.9 (<30 years) to 46.3±6.5 (≥70 years), closely mirroring the increase in traditional cardiovascular risk factors with age. Additional analysis using CACS demonstrated that the Dr.Noon CVD score achieved an area under the curve of 0.80 (95% confidence interval, 0.80–0.81) for detecting any coronary calcification, defined as CACS >0, and an area under the curve of 0.82 (95% confidence interval, 0.81–0.83) for identifying significant calcification burden, defined as CACS >100.
Conclusions
Dr.Noon CVD scores were consistently correlated with age, conventional risk factors, and CACS, suggesting a potential role in broad-based cardiovascular risk stratification and in guiding personalized prevention strategies.

Review Articles

Sex-specific challenges in cardiovascular disease among women: gaps in recognition, diagnosis, and management: Mi-Seung Shin; Cardiovasc Prev Pharmacother. 2025;7(2):50-54. Published online April 25, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e8

4,384 View
34 Download
1 Citations

Abstract PDF

Despite being the leading cause of mortality among women, cardiovascular disease remains underrecognized and undertreated due to sex-related differences in clinical presentation, risk factors, and healthcare delivery. Women are often excluded from clinical trials, undergo fewer diagnostic evaluations, and are less likely to receive guideline-directed therapies. Additionally, female-specific risk factors, such as pregnancy-related disorders, early menopause, and autoimmune diseases, are frequently overlooked. Addressing these disparities through sex-specific risk assessment, increased clinician awareness, and inclusion of women in research is imperative to optimize prevention and treatment strategies and reduce cardiovascular disease-related morbidity and mortality in women.

Citations

Citations to this article as recorded by

Bridging the Gender Gap: The Urgent Need for Cardiovascular Data on Women
Jyotsna Maddury, Achukatla Kumar
Indian Journal of Cardiovascular Disease in Women.2025; 10: 165. CrossRef

Clinical impact and practical use of sodium-glucose cotransporter 2 inhibitors for patients with chronic kidney disease: Jang-Whan Bae; Cardiovasc Prev Pharmacother. 2025;7(2):44-49. Published online April 25, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e4

7,144 View
62 Download

Abstract PDF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed the treatment of both cardiovascular and renal diseases. Although originally developed for glycemic control in type 2 diabetes mellitus, these agents have demonstrated significant benefits by reducing cardiovascular events and slowing the progression of kidney disease, even in patients without diabetes. Landmark trials, including EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, and DAPA-HF, consistently demonstrated reductions in heart failure hospitalizations and renal deterioration among patients at high cardiovascular risk. However, many of these studies excluded patients with advanced chronic kidney disease (CKD), limiting the generalizability of their findings for this population. More recent investigations, such as CREDENCE, DAPA-CKD, and EMPA-KIDNEY, have focused on patients with CKD and confirmed that SGLT2 inhibitors offer significant renal and cardiovascular protection regardless of diabetic status. This review summarizes key clinical trials, outlining their design and outcomes with a particular emphasis on inclusion and exclusion criteria and the implications for CKD populations. Further, it discusses the practical application and safety considerations of SGLT2 inhibitors in nephrology, underscoring their emerging role as a fundamental therapeutic strategy in CKD management.

The prognostic role of lipoprotein(a) in cardiovascular disease: Eun-Jung Rhee; Cardiovasc Prev Pharmacother. 2025;7(1):9-12. Published online January 22, 2025; DOI: https://doi.org/10.36011/cpp.2025.7.e3

2,525 View
36 Download

Abstract PDF: Lipoprotein(a) (Lp(a)), is not a new entity; however, it has become an increasingly discussed and studied risk factor for atherosclerotic cardiovascular disease (CVD) and aortic valve stenosis. Recent guidelines recommend measuring Lp(a) levels throughout the lifetime in patients at high risk for CVD, as Lp(a) can serve as a signature marker for identifying individuals at elevated risk for CVD. Numerous genetic and epidemiological studies have underscored the significant causal role of Lp(a) in the incidence of CVD. Individuals with high Lp(a) levels face an increased risk for CVD, even with optimal low-density lipoprotein cholesterol lowering. Furthermore, Lp(a) levels are primarily determined by genetics and are not significantly reduced by lifestyle changes or certain medications. This review will discuss the characteristics, genetic factors, and epidemiological properties of Lp(a) in relation to CVD.

Relationship between autonomic and peripheral neuropathies and cardiovascular outcomes in diabetes: Jae-Seung Yun; Cardiovasc Prev Pharmacother. 2024;6(4):123-127. Published online October 31, 2024; DOI: https://doi.org/10.36011/cpp.2024.6.e17

7,307 View
50 Download
1 Citations

Abstract PDF

This review explores the complex relationship between diabetic neuropathy and cardiovascular disease (CVD). Neuropathy, a common complication of type 1 and type 2 diabetes, is divided into autonomic and peripheral types, each impacting cardiovascular health. Cardiovascular autonomic neuropathy, a form of autonomic neuropathy, is associated with various CVD complications, including arrhythmias, impaired nocturnal blood pressure regulation, and increased mortality. The prevalence of cardiovascular autonomic neuropathy varies depending on the type and duration of diabetes and is influenced by factors like glycemic control and metabolic stress. Peripheral polyneuropathy, which is often linked to diabetic foot disease, is also correlated with elevated CVD risk; research suggests shared pathophysiological mechanisms between peripheral neuropathy and cardiovascular conditions. Screening for neuropathies using tools like the Michigan Neuropathy Screening Instrument and heart rate variability analyses can facilitate early detection of CVD risk. Additionally, emerging technologies, like deep learning models, have demonstrated promise in detecting early cardiovascular patterns associated with autonomic neuropathy through electrocardiogram analysis. These findings underscore the value of integrating novel diagnostic approaches for early intervention. As CVD represents a leading cause of death among patients with diabetes, this article emphasizes the need for thorough assessment and proactive management of neuropathy to mitigate cardiovascular risk. The review recommends a multidisciplinary approach to diabetes care, including early screening, accurate risk stratification, and targeted therapeutic strategies to prevent or slow the progression of CVD in patients with autonomic and peripheral neuropathies. Further research is warranted to clarify the optimal intervention strategies for reducing CVD risk in these populations.

Citations

Citations to this article as recorded by

Association between physical activity propensity and cardiovascular autonomic neuropathy in type 1 diabetes: evidence from a single-centre study
Simona Zaccaria, Laura Giurato, Isabella Nardone, Sium Wolde Sellasie, Innocenza Tripicchio, Marco Meloni, Pasquale Di Perna, Luigi Uccioli
Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef

Sodium-glucose cotransporter 2 inhibitors in cardiocerebrovascular disease: Jin Joo Park; Cardiovasc Prev Pharmacother. 2024;6(4):103-108. Published online October 31, 2024; DOI: https://doi.org/10.36011/cpp.2024.6.e16

6,788 View
39 Download

Abstract PDF: Cardiovascular disease is a leading cause of global mortality, necessitating effective strategies for prevention and treatment. The cardiovascular disease continuum concept highlights the progression from risk factors such as hypertension and diabetes mellitus to advanced stages, including heart failure (HF) and death. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed to manage diabetes, have emerged as effective therapies across all stages of the cardiovascular disease continuum. Numerous cardiovascular outcome trials demonstrate that SGLT2 inhibitors significantly reduce major adverse cardiovascular events and hospitalizations for HF in patients with and without established atherosclerotic cardiovascular disease. Notably, SGLT2 inhibitors have shown remarkable benefits in reducing HF risk, even in patients without diabetes, including those with HF and preserved ejection fraction. Furthermore, recent studies in post–myocardial infarction patients suggest potential benefits in reducing hospitalizations for HF. Despite their widespread use, the precise mechanisms by which SGLT2 inhibitors confer cardiovascular protection remain unclear, suggesting the need for further investigation. In conclusion, SGLT2 inhibitors have revolutionized cardiovascular disease management, offering significant therapeutic potential across a broad spectrum of patients, and are expected to play an increasingly prominent role in both the prevention and treatment of cardiovascular disease.

Original Articles

Health behaviors, knowledge, and attitudes toward cardiovascular disease risk factors in young Iraqi adults: a sample from Erbil, Iraq: Halmat Ahmed Sulaiman, Isil Isik Andsoy; Cardiovasc Prev Pharmacother. 2024;6(3):92-101. Published online July 30, 2024; DOI: https://doi.org/10.36011/cpp.2024.6.e12

9,205 View
169 Download

Abstract PDF: Background
Cardiovascular disease continues to be a leading cause of death among young people globally. This cross-sectional study was designed to assess the health behaviors, knowledge, and attitudes regarding cardiovascular disease risk factors among young adults in Erbil, Iraq.
Methods
Data were collected using the WHO STEPS Instrument for Chronic Disease Risk Factor Surveillance and the Heart Disease Fact Questions.
Results
Ninety percent of participants demonstrated moderate to high knowledge and exhibited a positive attitude. Multiple linear regression analysis revealed that while a history of smoking, a lack of knowledge, and the absence of formal education negatively impacted knowledge levels, being aged 38 to 45 years, recognizing the importance of consuming less salt, walking for at least 10 minutes on 5 or more days per week, and regularly checking blood sugar levels positively contributed to knowledge. Unwillingness to change lifestyle had the most significant negative influence on knowledge.
Conclusions
Establishing effective educational interventions may increase knowledge and promote more positive attitudes.

Changes in cardiovascular-related health behaviors after the end of social distancing: the 2023 Cardiovascular Disease Prevention Awareness Survey: Jaeyong Lee, Eunji Kim, Won-Young Lee, Eun-Jung Rhee, Hyeon Chang Kim; Cardiovasc Prev Pharmacother. 2024;6(2):57-64. Published online April 5, 2024; DOI: https://doi.org/10.36011/cpp.2024.6.e6

3,735 View
23 Download

Abstract PDF Supplementary Material: Background
The COVID-19 pandemic and the implementation of social distancing have been reported to negatively impact cardiovascular-related health behaviors. However, the effects of lifting social distancing restrictions on these health behaviors remain unclear. This study investigated public awareness and behavioral changes related to cardiovascular disease prevention after the end of social distancing.
Methods
Between June 5 and June 12, 2023, 2,000 adults participated in the 2023 Cardiovascular Disease Prevention Awareness Survey in Korea. The survey comprehensively addressed sociodemographic factors, cardiometabolic disease history, cardiovascular disease concern, prevention awareness, and behavioral changes after the end of social distancing. Logistic regression analyses were performed to assess the associations between behavioral changes and sociodemographic factors.
Results
Cardiovascular disease ranked as the second most feared disease (most feared, 18.0%; second most feared, 26.3%) after cancer (most feared, 42.3%; second most feared, 21.7%). Among nine cardiovascular disease prevention recommendations, stress management, being physically active, and maintaining a healthy diet were perceived as the most challenging recommendations. After the end of social distancing, there were more positive changes than negative changes in smoking, alcohol consumption, dietary habits, physical activity, and healthcare service use, whereas stress management more frequently changed negatively (40.0%) than it changed positively (19.5%).
Conclusions
Positive changes in cardiovascular-related health behaviors, except for stress management, were observed after the end of social distancing. Further research is necessary to fully comprehend the impact of discontinuing social distancing practices.

Review Articles

COVID-19 vaccination–related cardiovascular complications: Jae Yeong Cho, Kye Hun Kim; Cardiovasc Prev Pharmacother. 2023;5(4):134-143. Published online October 27, 2023; DOI: https://doi.org/10.36011/cpp.2023.5.e17

17,118 View
61 Download
1 Citations

Abstract PDF

The global response to the COVID-19 pandemic has led to rapid vaccine development and distribution. As vaccination efforts continue, concerns have arisen regarding potential adverse events associated with COVID-19 vaccination. This article examines emerging evidence on adverse events, including myocarditis, pericarditis, and thrombotic complications, in relation to COVID-19 vaccination. Reports of myocarditis and pericarditis cases following messenger RNA vaccines have sparked interest, with discussions revolving around potential mechanisms and genetic predispositions. The contrasting findings on pericarditis risk postvaccination highlight the complexity of studying this phenomenon. Thrombotic events, particularly vaccine-induced thrombotic thrombocytopenia, have garnered attention, prompting investigations into antibody responses and mechanisms. This article underscores the importance of ongoing research, collaboration, and data analysis for accurately understanding adverse events. While the COVID-19 vaccination campaign may have ended, it is still vital to maintain vigilance, collect comprehensive data and foster interdisciplinary collaboration to uphold vaccine safety and steer public health strategies in the upcoming period.

Citations

Citations to this article as recorded by

The Role of COVID-19 Vaccination for Patients With Atherosclerotic Cardiovascular Disease in the Upcoming Endemic Era
Kye Hun Kim
Journal of Lipid and Atherosclerosis.2024; 13(1): 21. CrossRef

Optimal target blood pressure in older patients with hypertension: Kwang-il Kim; Cardiovasc Prev Pharmacother. 2023;5(2):41-48. Published online April 24, 2023; DOI: https://doi.org/10.36011/cpp.2023.5.e4

44,902 View
522 Download
1 Citations

Abstract PDF

Hypertension is a common condition among older adults, and blood pressure (BP) control is effective for preventing cardiovascular morbidity and mortality even among the oldest-old adults. However, the optimal target BP for older patients with hypertension has been a subject of debate, with previous clinical trials providing conflicting evidence. Determining the optimal target BP for older adults is a complex issue that requires considering comorbidities, frailty, quality of life, and goals of care. As such, BP targets should be individualized based on each patient's unique health status and risk factors, and treatment should be closely monitored to ensure that it is effective and well-tolerated. The benefits and risks of intensive BP control should be carefully weighed in the context of the patient's overall health status and treatment goals. Ultimately, the decision to pursue intensive BP control should be made through shared decision-making between patients and their healthcare providers.

Citations

Citations to this article as recorded by

Community health worker-led interventions for hypertension
Suning Mao, Liu Liu, Tianyi Wang, Yubin Cao
Cochrane Database of Systematic Reviews.2025;[Epub] CrossRef

Original Articles

Changes in cardiovascular-related health behaviors during the COVID-19 pandemic: Eunji Kim, Chan-Hee Jung, Dae Jung Kim, Seung-Hyun Ko, Hae-Young Lee, Kyung-Yul Lee, Dae Ryong Kang, Sung Kee Ryu, Won-Young Lee, Eun-Jung Rhee, Hyeon Chang Kim; Cardiovasc Prev Pharmacother. 2023;5(1):15-23. Published online January 27, 2023; DOI: https://doi.org/10.36011/cpp.2023.5.e2

5,853 View
60 Download
2 Citations

Abstract PDF Supplementary Material

Background
The COVID-19 pandemic has been the most pressing health challenge in recent years. Meanwhile, prevention for other diseases, such as cardiovascular disease (CVD) has been less prioritized during the pandemic. COVID-19, a novel infectious disease, both had a direct impact on public health and provoked changes in health-related behaviors, including those for CVD prevention. This study sought to examine changes in CVD-related health behaviors during the COVID-19 pandemic and related sociodemographic factors.
Methods
We used data from the Cardiovascular Disease Prevention Awareness Survey conducted in Korea in June 2022. A total of 2,000 adults across Korea’s 17 provinces completed a structured questionnaire online or on a mobile device. Self-reported changes in CVD-related health behaviors were investigated. We used unadjusted and adjusted logistic regression models to explore the associations between negative changes and sociodemographic factors.
Results
In smoking, drinking, and healthcare service use, the proportion of those with positive changes surpassed the proportion of respondents who reported negative changes. In contrast, negative changes predominated for diet, exercise, and stress. Most individuals (52.6%) reported a deterioration of psychological distress. These negative changes were significantly associated with age, sex, marital status, and the presence of cardiometabolic disease.
Conclusions
The COVID-19 pandemic has affected CVD-related health behaviors. Based on these changes, CVD prevention should be encouraged with appropriate and prioritized strategies.

Citations

Citations to this article as recorded by

Changes in cardiovascular-related health behaviors after the end of social distancing: the 2023 Cardiovascular Disease Prevention Awareness Survey
Jaeyong Lee, Eunji Kim, Won-Young Lee, Eun-Jung Rhee, Hyeon Chang Kim
Cardiovascular Prevention and Pharmacotherapy.2024; 6(2): 57. CrossRef
Cardiovascular-related health behavior changes: lessons from the COVID-19 pandemic and post-pandemic challenges
Inha Jung, Won-Young Lee
Cardiovascular Prevention and Pharmacotherapy.2023; 5(4): 99. CrossRef

Public awareness of cardiovascular disease prevention in Korea: Eunji Kim, Chan-Hee Jung, Eun-Jung Rhee, Junghyun Noh, Jae Hyuk Lee, Hun-Jun Park, Sungha Park, Sang-Hyun Ihm, Won-Young Lee, Hyeon Chang Kim; Cardiovasc Prev Pharmacother. 2022;4(4):149-157. Published online October 26, 2022; DOI: https://doi.org/10.36011/cpp.2022.4.e20

6,648 View
59 Download
1 Citations

Abstract PDF Supplementary Material

Background
The burden of cardiovascular disease (CVD) is significant in Korea. Ultimately, public knowledge and awareness of CVD risk factors and prevention are essential to reduce its burden. Hence, this study aimed to examine the level of public awareness of CVD risk factors and prevention in Korea in 2022.
Methods
We used data from the Cardiovascular Disease Prevention Awareness Survey conducted by the Korean Society of Cardiovascular Disease Prevention in June 2022. Using a structured web-based questionnaire, 2,000 individuals aged 20 years or more were surveyed on computers or mobile devices. Information on sociodemographic characteristics, the presence of cardiometabolic disease, CVD concerns and self-assessed likelihood, and awareness of CVD prevention were analyzed.
Results
Cancer (44.3%) was the most feared disease, followed by CVD (19.5%). Nevertheless, most respondents stated that they were likely to develop CVD in their lifetime (67.4%). Only 9.2% of respondents were aware of the details of recommendations to prevent CVD, and this level of knowledge was also low among respondents with cardiometabolic diseases (10.7%). Not smoking, being physically active, eating a healthy diet, and reducing alcohol consumption were deemed easy to implement. On the contrary, reducing stress, being physically active, and eating a healthy diet were considered the most difficult recommendations to practice.
Conclusions
Public awareness of CVD risk factors and prevention appeared to be insufficient in Korea. Our research suggests that simple but practical recommendations should be conveyed and promoted to raise public awareness, which is currently inadequate.

Citations

Citations to this article as recorded by

Guidelines for Holter and Wearable Electrocardiogram Monitoring in Arrhythmia Diagnosis and the Role of Medical Technologists
Do-Hee KIM, Ji-Yeon CHANG
Korean Journal of Clinical Laboratory Science.2025; 57(2): 215. CrossRef

Review Articles

Cardiovascular diseases in HIV patients: Hyun-Ha Chang; Cardiovasc Prev Pharmacother. 2022;4(3):95-98. Published online July 29, 2022; DOI: https://doi.org/10.36011/cpp.2022.4.e14

5,650 View
97 Download
1 Citations

Abstract PDF

New and more effective antiretroviral therapy regimens have increased viral suppression and improved immune function recovery, leading to the extension of the lifespan of people living with HIV (PLWH). The extended lifespan of PLWH has recently been reported as a significant factor associated with diabetes mellitus, dyslipidemia, and long-term metabolic consequences, such as cardiovascular diseases. Therefore, this article briefly reviews the epidemiology and risk factors of cardiovascular diseases, including dyslipidemia and diabetes mellitus, in PLWH.

Citations

Citations to this article as recorded by

Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians
Ceren Aydemir, Raniah Al Saidi, Ji Soo Choi, Mohamed H. Ahmed, Dushyant Mital
Journal of Family Medicine and Primary Care.2024; 13(12): 5920. CrossRef

Body Weight Change and Cardiovascular Disease: Effect of Weight Gain, Weight Loss, and Weight Cycling: Jung-Hwan Cho, Eun-Jung Rhee, Won-Young Lee; Cardiovasc Prev Pharmacother. 2021;3(4):73-81. Published online October 31, 2021; DOI: https://doi.org/10.36011/cpp.2021.3.e12

12,340 View
147 Download
1 Citations

Abstract PDF

Obesity is an independent risk factor for the development and progression of cardiovascular disease (CVD). Various cardiovascular outcomes are related to the association between body weight change and CVD. Metabolically healthy obese individuals could have a better prognosis in terms of cardiovascular morbidity and mortality than metabolically unhealthy obese individuals. Smoking cessation causes significant weight gain and consequent deterioration of the metabolic profile despite not impairing the cardiovascular benefits. Intentional weight loss has a consistent cardiovascular protective effect, but unintentional weight loss due to progressive catabolism and loss of muscle mass could be associated with poor cardiovascular outcomes. Obese individuals who are successful in losing weight with subsequent regain (weight cycling) could have an unfavorable cardiometabolic profile and the risk of CVD. Further studies are needed to evaluate the impact of weight changes on CVD by identifying unknown pathophysiology and to decide appropriate management and interventions for various phenotypes of weight change.

Citations

Citations to this article as recorded by

Investigating the efficacy and feasibility of using a whole-of-diet approach to lower circulating levels of C-reactive protein in postmenopausal women: a mixed methods pilot study
Stephanie Cowan, Aimee Dordevic, Andrew J. Sinclair, Helen Truby, Surbhi Sood, Simone Gibson
Menopause.2023; 30(7): 738. CrossRef

Special Article

Geriatric Considerations in the Management of Elderly Patients with Cardiovascular Diseases: Doo Soo Jeon; Cardiovasc Prev Pharmacother. 2021;3(2):38-46. Published online April 30, 2021; DOI: https://doi.org/10.36011/cpp.2021.3.e6

13,648 View
255 Download
1 Citations

Abstract PDF

Cardiovascular disease (CVD) is the most frequently diagnosed disease as well as the leading cause of death in the elderly. It usually results from long-term effects of cardiovascular risk factors as well as the aging process itself. Elderly people commonly have geriatric syndrome, which is an age-specific problem that is complicated by the presence of cardiovascular, cognitive, and physical dysfunction and is accompanied by many other chronic diseases. While caring for the elderly, in addition to CVD, various inherent problems must be considered. The patient-centered approach, instead of evidence-based guidelines that are designed for young adult patients, is the most important concept when it comes to elderly patients with CVD and multiple comorbidities. This approach should be used to maintain the functionality, independence, quality of life, and dignity of these patients.

Citations

Citations to this article as recorded by

Assessment of Quality of Life in Patients With Cardiovascular Disease Using the SF-36, MacNew, and EQ-5D-5L Questionnaires
Aikaterini Chatzinikolaou, Stergios Tzikas, Maria Lavdaniti
Cureus.2021;[Epub] CrossRef

Original Article

Changes in Target Achievement Rates after Statin Prescription Changes at a Single University Hospital: Seon Choe, Jiwon Shinn, Hun-Sung Kim, Ju Han Kim; Cardiovasc Prev Pharmacother. 2020;2(3):103-111. Published online July 31, 2020; DOI: https://doi.org/10.36011/cpp.2020.2.e14

5,714 View
20 Download
1 Citations

Abstract PDF

Background
We investigated the changes in low-density lipoprotein cholesterol (LDL-C) target achievement rates (<70 and <100 mg/dL) when the prescription changed from various statins to Lipilou^®, a generic formulation of atorvastatin.
Methods
This was a retrospective cohort study of patients who had been prescribed Lipilou^® for more than 3 months at Seoul National University Hospital from 2012 to 2018. For patients who were treated with a previous statin before the prescription of Lipilou^®, changes in target achievement rates of LDL-C less than 70 and less than 100 mg/dL were confirmed 3–6 months after the prescription of Lipilou^®.
Results
Among the 683 enrolled patients, when their prescription was changed to Lipilou^®, the target achievement rate of LDL-C significantly increased for LDL-C less than 70 mg/dL (from 22.1% to 66.2%, p<0.001) and less than 100 mg/dL (from 26.8% to 75.3%, p<0.001). In particular, when a moderate-low potency statin was changed to Lipilou^® (10 mg), the target achievement rates for LDL-C less than 70 mg/dL (from 28.9% to 66.7%, p<0.001) and less than 100 mg/dL (from 42.2% to 86.7%, p<0.001) significantly increased. The change from a moderate-high potency statin to Lipilou^® (20 mg) showed an increased target achievement rates for LDL-C <70 mg/dL (from 33.3% to 80.0%, p=0.008) and 100 mg/dL (from 40.0% to 73.3%, p<0.025).
Conclusions
We cannot simply conclude that Lipilou^® is superior to other statins. However, when the target LDL-C was not reached with previous statin treatments, a high target achievement rate could be achieved by changing the prescription to Lipilou^®. Physicians should always consider aggressive statin prescription changes for high target achievement rates.

Citations

Citations to this article as recorded by

Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research
Dae-Sung Kyoung, Hun-Sung Kim
Journal of Lipid and Atherosclerosis.2022; 11(2): 103. CrossRef

Special Article

Effects of Low-Carbohydrate, High-Fat Diets on Weight Loss, Cardiovascular Health and Mortality: Bo-Yeon Kim; Cardiovasc Prev Pharmacother. 2020;2(2):43-49. Published online April 30, 2020; DOI: https://doi.org/10.36011/cpp.2020.2.e7

34,777 View
76 Download
1 Citations

Abstract PDF

Obesity is a worldwide health challenge. The clinical consequences of obesity include nonalcoholic fatty liver disease, type 2 diabetes, and coronary heart disease. Numerous diets have been developed to reduce the incidence of cardiovascular diseases and induce weight loss. Low-carbohydrate, high-fat diets (LCHFDs) have become increasingly popular for weight loss. LCHFDs have led to weight loss in some clinical studies. However, the safety of LCHFDs and their long-term effects on the human body are still controversial. In this review, I will discuss the effects of LCHFDs on weight loss, cardiovascular health, and mortality.

Citations

Citations to this article as recorded by

Cholesterol, fatty acids profile and the indices of atherogenicity and thrombogenicity of raw lamb and mutton offal
B. Pretorius, H.C. Schönfeldt
Food Chemistry.2021; 345: 128868. CrossRef

Review Articles

Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective: Doo Soo Jeon; Cardiovasc Prev Pharmacother. 2020;2(1):11-17. Published online January 31, 2020; DOI: https://doi.org/10.36011/cpp.2020.2.e4

5,213 View
52 Download

Abstract PDF: Type 2 diabetes mellitus (T2DM) is a complex disorder and is associated with an increased risk for developing atherosclerotic cardiovascular disease. Control of major risk factors of T2DM can reduce major adverse cardiovascular events (MACEs) in patients. Glycemic control has long been the gold standard for treatment of T2DM. However, strict blood glucose control strategies have repeatedly failed in the prevention of cardiovascular events in key clinical trials. The 2019 American and European practice guidelines for the prevention of cardiovascular disease in patients with T2DM have recommended the use of novel hypoglycemic agents, such as sodium glucose transporter 2 inhibitors and glucagonlike peptide-1 receptor antagonist, which have shown significant reductions in the risk of MACE in spite of their modest glycemic control capacity. A paradigm shift from the glucosecentered approach in treating diabetic patients with cardiovascular disease is imperative. Based on positive outcomes from previous evidence, the reduction of the risk of MACE should be a primary objective for treatment.

Pregnancy at Late Maternal Age and Future Cardiovascular Health: Mi-Jeong Kim; Cardiovasc Prev Pharmacother. 2019;1(2):50-56. Published online October 31, 2019; DOI: https://doi.org/10.36011/cpp.2019.1.e9

6,263 View
33 Download

Abstract PDF: Increasing numbers of women are delivering their first child at a later age. First pregnancy at a later age is, per se, a high-risk pregnancy. Pregnancy after 35 years is traditionally considered a late maternal age. The risks of obstetric complications including fetal and maternal complications are increased. Defective placenta syndrome, including hypertensive disorders, preterm birth, and intrauterine growth retardation, shares similar pathophysiologic mechanisms with endothelial dysfunction, although their clinical presentations differ. Recent medical advances have improved the medical performance of pregnancy-related cardiovascular disease (CVD). Recent evidence has shown that women with underlying defective placental syndrome or other pregnancy-related complications have an increased risk of unfavorable cardiovascular outcomes in later life. An increasing number of women delivering their first child at a later age have epidemiological characteristics that differ from those reported previously and for which data are limited data regarding the cardiovascular prognosis. Therefore, increased attention to public health and CVD prevention is required for women with complicated pregnancies.

First
Prev
Page of 1
Next
Last

Search